- Home
- ACRE vs SLN Comparison
ACRE vs SLN Comparison
Compare ACRE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- SLN
- Stock Information
- Founded
- ACRE 2011
- SLN 1994
- Country
- ACRE United States
- SLN United Kingdom
- Employees
- ACRE N/A
- SLN N/A
- Industry
- ACRE Real Estate Investment Trusts
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- ACRE Real Estate
- SLN Health Care
- Exchange
- ACRE Nasdaq
- SLN Nasdaq
- Market Cap
- ACRE 242.6M
- SLN 268.8M
- IPO Year
- ACRE 2012
- SLN N/A
- Fundamental
- Price
- ACRE $4.63
- SLN $7.14
- Analyst Decision
- ACRE Hold
- SLN Buy
- Analyst Count
- ACRE 5
- SLN 6
- Target Price
- ACRE $4.83
- SLN $39.67
- AVG Volume (30 Days)
- ACRE 368.7K
- SLN 173.3K
- Earning Date
- ACRE 11-06-2025
- SLN 11-13-2025
- Dividend Yield
- ACRE 12.93%
- SLN N/A
- EPS Growth
- ACRE N/A
- SLN N/A
- EPS
- ACRE N/A
- SLN N/A
- Revenue
- ACRE $80,674,000.00
- SLN $27,169,000.00
- Revenue This Year
- ACRE N/A
- SLN N/A
- Revenue Next Year
- ACRE N/A
- SLN N/A
- P/E Ratio
- ACRE N/A
- SLN N/A
- Revenue Growth
- ACRE 58.54
- SLN 22.28
- 52 Week Low
- ACRE $3.35
- SLN $1.97
- 52 Week High
- ACRE $7.49
- SLN $18.32
- Technical
- Relative Strength Index (RSI)
- ACRE 50.50
- SLN 66.41
- Support Level
- ACRE $4.41
- SLN $6.89
- Resistance Level
- ACRE $4.76
- SLN $7.78
- Average True Range (ATR)
- ACRE 0.13
- SLN 0.58
- MACD
- ACRE 0.02
- SLN 0.15
- Stochastic Oscillator
- ACRE 63.16
- SLN 77.12
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.